Development of specific T-cell responses to Candida and tetanus antigens in partial DiGeorge syndrome

Journal of Allergy and Clinical Immunology

Volumn 122, Issue 6, 2008, Pages 1194-1199

  Davis, Carla M ^a   Kancherla, Vikas S ^a   Reddy, Ashwini ^a   Chan, Wenyaw ^b   Yeh, Hung Wen ^c   Noroski, Lenora M ^a   Rosenblatt, Howard ^a,d   Shearer, William T ^a   Chinen, Javier ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^d DELL INC   (United States)

Author keywords

22q11 deletion; Candida species immunity; Partial DiGeorge syndrome; T cell deficiency; tetanus immunity; velocardiofacial syndrome

Indexed keywords

ANTIGEN; CANDIDA ANTIGEN; CD3 ANTIGEN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; IMMUNOGLOBULIN G; TETANUS ANTIGEN; UNCLASSIFIED DRUG;

ADOLESCENT; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; CELL COUNT; CELLULAR IMMUNITY; CHILD; CHROMOSOME 22Q; CONTROLLED STUDY; DIGEORGE SYNDROME; FEMALE; HUMAN; HUMORAL IMMUNITY; INFANT; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; T LYMPHOCYTE;

ADOLESCENT; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; ANTIGENS, CD3; ANTIGENS, FUNGAL; CANDIDA; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; DIGEORGE SYNDROME; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; LYMPHOCYTE COUNT; MALE; RETROSPECTIVE STUDIES; T-LYMPHOCYTES; TETANUS TOXOID;

EID: 57149131812     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2008.06.039     Document Type: Article

References (20)

1. Botto L.D., May K., Fernhoff P.M., Correa A., Coleman K., Rasmussen S.A., et al. A population based study of the 22q11.2 deletion: phenotype, incidence and contribution to major birth defects in the population. Pediatrics 112 (2003) 101-107
2. Sullivan K.E. The clinical, immunological, and molecular spectrum of chromosome 22q11.2 deletion syndrome and DiGeorge syndrome. Curr Opin Allergy Clin Immunol 4 (2004) 505-512
3. Markert M.L., Devlin B.H., Alexieff M.J., Li J., McCarthy E.A., Gupton S.E., et al. Review of 54 patients with complete DiGeorge anomaly enrolled in protocols for thymus transplantation: outcome of 44 consecutive transplants. Blood 109 (2007) 4539-4547
4. Jawad A.F., McDonald-McGinn D.M., Zackai E., and Sullivan K.E. Immunologic features of chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). J Pediatr 139 (2001) 715-723
5. Bonilla F.A., Bernstein I.L., Khan D.A., Ballas Z.K., Chinen J., Frank M.M., et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 94 suppl 1 (2005) S1-S63
6. American Academy of Pediatrics. Immunocompromised children, immunization in special clinical circumstances. In: Pickering L.K., Baker C.J., Long S.S., and McMillan J.A. (Eds). Red book: 2006 report of the Committee on Infectious Diseases. 27th ed. (2006), American Academy of Pediatrics, Elk Grove Village (IL) 73
7. Perez E.E., Bokszczanin A., McDonald-McGinn D., Zackai E.H., and Sullivan K.E. Safety of live viral vaccines in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Pediatrics 112 (2003) e325
8. Azzari C., Gambineri E., Resti M., Moriondo M., Betti L., Saldias L.R., et al. Safety and immunogenicity of measles-mumps-rubella vaccine in children with congenital immunodeficiency (DiGeorge syndrome). Vaccine 23 (2005) 1668-1671
9. Moylett E.H., Wasan A.N., Noroski L.M., and Shearer W.T. Live viral vaccines in patients with partial DiGeorge syndrome: clinical experience and cellular immunity. Clin Immunol 112 (2004) 106-112
10. Sullivan K.E., McDonald-McGinn D., Driscoll D.A., Emanuel B.S., Zackai E.H., and Jawad A.F. Longitudinal analysis of lymphocyte function and numbers in the first year of life in chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Clin Diagn Lab Immunol 6 (1999) 906-911
11. Barrett D.J., Ammann A.J., Wara D.W., Cowan M.J., Fisher T.J., and Stiehm E.R. Clinical and immunologic spectrum of the DiGeorge syndrome. J Clin Lab Immunol 6 (1981) 1-6
12. Bastian J., Law S., Vogler L., Lawton A., Herrod H., Anderson S., et al. Prediction of persistent immunodeficiency in the DiGeorge anomaly. J Pediatr 115 (1989) 391-396
13. Chinen J., Rosenblatt H.M., Smith E.O., Shearer W.T., and Noroski L.M. Long-term assessment of T-cell populations in DiGeorge syndrome. J Allergy Clin Immunol 111 (2003) 573-579
14. Shearer W.T., Rosenblatt H.M., Gelman R.S., Oyomopito R., Plaeger S., Stiehm E.R., et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol 112 (2003) 973-980
15. Piliero L.M., Sanford A.N., McDonald-McGinn D.M., Zackai E.H., and Sullivan K.E. T-cell homeostasis in humans with thymic hypoplasia due to chromosome 22q11.2 deletion syndrome. Blood 103 (2004) 1020-1025
16. Junker A.K., and Driscoll D.A. Humoral immunity in DiGeorge syndrome. J Pediatr 127 (1995) 231-237
17. Sedivá A., Bartůnková J., Zachová R., Poloucková A., Hrusák O., Janda A., et al. Early development of immunity in diGeorge syndrome. Med Sci Monit 11 (2005) 182-187
18. Waters V., Peterson K.S., and LaRussa P. Live viral vaccines in a DiGeorge syndrome patient. Arch Dis Child 92 (2007) 519-520
19. Pierdominici M., Mazzetta F., Caprini E., Marziali M., Digilio M.C., Marino B., et al. Biased T-cell receptor repertoires in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Clin Exp Immunol 132 (2003) 323-331
20. Cancrini C., Romiti M.L., Finocchi A., Di Cesare S., Ciaffi P., Capponi C., et al. Post-natal ontogenesis of the T-cell receptor CD4 and CD8 Vbeta repertoire and immune function in children with DiGeorge syndrome. J Clin Immunol 25 (2005) 265-274